Boston Scientific to pay up to $265M for Rhythmia Medical

Tue, 10/09/2012 - 10:02am
Mass Device

Boston Scientific agrees to pay up to $265 million for Rhythmia Medical and its heart-mapping technology

Boston Scientific
Rhythmia Medical

Boston Scientific (NYSE:BSX) said it's agreed to pony up $90 million in cash and perhaps another $175 million to acquire Rhythmia Medical and its heart-mapping technology.

The deal, expected to close by the end of this week, hinges on a series of regulatory and commercial milestones through 2017 for Burlington, Mass.-based Rhythmia and its closely-held device for mapping and navigating the heart during catheter ablation procedures to treat atrial fibrillation.

Boston Scientific said it expects the Rhythmia system to win FDA clearance and CE Mark approval in the European Union in time for a limited launch next year and a full-on début in 2014.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.